FIELD: medicine.
SUBSTANCE: invention refers to a method of treating ocular neovascularisation, angiogenesis, retinal hypostasis, diabetic retinopathy, and/or retinal ischemia to prevent visual acuity loss associated with such conditions. The invention provides introduction to a patient requiring of a composition containing therapeutically effective amount of receptor tyrosine kinase inhibitor that blocks tyrosine auto-phosphorylation of 2 VEGF receptor with IC50 less than 10 nM and of at least one receptor chosen from the group including receptor 1 VEGF, receptor 3 VEGF, Tie-2, PDGFR, c-KIT, Flt-3 and CSF-IR with IC50 less than 100 nM.
EFFECT: method allows preventing visual acuity loss associated with eye neovascularisation, angiogenesis, retinal hypostasis, diabetic retinopathy, and/or retinal ischemia.
17 cl, 5 tbl, 9 dwg, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING OPHTHALMIC ANGIOGENESIS, RETINAL OEDEMA, RETINAL ISCHEMIA AND DIABETIC RETINOPATHY WITH USING SELECTIVE RTK INHIBITORS | 2006 |
|
RU2445096C2 |
| OPHTHALMOLOGICAL PHARMACEUTICAL COMPOSITIONS FOR NEOANGIOGENIC EYE PATHOLOGIES | 2009 |
|
RU2519739C2 |
| ANTHRANILIC ACID AND THIOANTHRANILIC ACID N-ARYLAMIDES | 1999 |
|
RU2286338C2 |
| APPLICATION OF ANTAGONIST VEGF IN TREATMENT OF CHORIORETINAL NEOVASCULAR DISTURBANCES AND DISORDERS OF PENETRATION IN PEDIATRIC PATIENTS | 2014 |
|
RU2676274C2 |
| SUBSTITUTED PYRAZOLOPYRIDINES, CONTAINING COMPOSITIONS, METHOD FOR MAKING AND APPLICATION | 2006 |
|
RU2375360C2 |
| ANTHRANILIC ACID AMIDES AND THEIR USING IN PHARMACEUTICALS | 2002 |
|
RU2315756C2 |
| THIENO[3,2-c]PYRIDINE DERIVATIVES AS KINASE INHIBITORS FOR USE IN CANCER TREATMENT | 2009 |
|
RU2480472C2 |
| PROTEIN TYROSINE KINASE ACTIVITY INHIBITORS | 2009 |
|
RU2533827C2 |
| SUBSTITUTED DIALKYL (OXIDE)-Λ-SULFANILIDENE NICOTINAMIDE DERIVATIVES AS KINASE INHIBITORS | 2014 |
|
RU2711749C2 |
| INTEGRIN RECEPTOR ANTAGONISTS AND USE THEREOF | 2012 |
|
RU2721907C2 |
